By uncovering the anti-tumor and immune-related mechanisms of fosinopril via GSDME-mediated pyroptosis, this work offers new insights for developing low-toxicity, high-efficiency anti-cancer therapies and highlights potential breakthroughs in the clinical treatment of NSCLC. Here, GSDME is linked to non-small cell lung carcinoma.